The Latest Cardiac and Vascular News
Strong R&D progress & attractive commercial deals, including additional Tranexamic Acid RTU out-licensing deals Potential U.S. market approval for Maxigesic® IV in H2 2023 Promising new product candidates driving innovation and on track for a planned acceleration towards a portfolio of 30 assets before 2025 Revenues of €3 million, net […]
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 1 April 2022, 07:00 CET LIÈGE, Belgium , April 01, […]
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. REGULATED INFORMATION – INSIDE INFORMATION LIÈGE, Belgium, March 31, 2022 (GLOBE NEWSWIRE) — Hyloris Pharmaceuticals SA (Euronext Brussels: […]
Added 4 additional innovative product candidates Strong growth in H2 leading to total revenues of €3.1 million (€0.2 million in 2020) Significant expansion of commercial footprint of Maxigesic® IV Tranexamic RTU licensing extended beyond U.S. €50 million in cash and cash equivalents to execute ambitious growth strategy LIÈGE, Belgium, March […]
Potential to revolutionise the current treatment paradigm and become the cornerstone therapy for patients with suspected acute coronary syndrome Enables accelerated development of HY-073 (IV acetylsalicylic acid), bringing the anticipated FDA submission date forward to end 2023 Initially targeting a total addressable patient population of ~2 million in the U.S. […]
Patient-friendly alternative to continuous IV administration – proven safety and efficacy Targeting orphan, late-stage heart failure indication with high unmet medical needs Liège, Belgium – 8 October 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces […]
